Document is current
Any future updates will be listed below
-
Authors
Ambery, Phil https://orcid.org/0000-0003-2978-1886
Bågenholm, Ralph
Pepper, Thomas
Barton, Claire M. https://orcid.org/0000-0002-6407-1479
Whitehead, Maria A.
Rodriguez, Lewis H. https://orcid.org/0009-0003-9337-4238
Greasley, Peter J. https://orcid.org/0000-0002-2529-4477
-
Funding
Funding for this research was provided by:
PTEN Research Foundation, a charity governed by English law (Medical writing)
- License Information
-
More Information
Article History
Received: 4 February 2026
Accepted: 8 July 2026
First Online: 22 July 2026
Declarations
Competing interests: PA and PJG are employees and shareholders in AstraZeneca, which is the marketing authorisation holder for dapagliflozin (an SGLT2 inhibitor) and also developing other agents for type 2 diabetes and obesity. The authors declare that there are no other relationships or activities that might bias, or be perceived to bias, their work.
